A detailed history of Baker Bros. Advisors LP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 4,004,756 shares of TSHA stock, worth $12.3 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
4,004,756
Previous 4,004,756 -0.0%
Holding current value
$12.3 Million
Previous $8.97 Million 10.27%
% of portfolio
0.09%
Previous 0.12%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $2 Million - $4.32 Million
1,500,000 Added 59.89%
4,004,756 $7.09 Million
Q3 2023

Nov 14, 2023

BUY
$0.63 - $3.66 $1.58 Million - $9.17 Million
2,504,756 New
2,504,756 $7.92 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $149M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.